zandelisib + zanubrutinib

Zandelisib (ME-401) + zanubrutinib is an investigational oral combination therapy consisting of a highly selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor (zandelisib/ME-401) and a potent Bruton's tyrosine kinase (BTK) inhibitor (zanubrutinib/Brukinsa)[3][7][9]. The combination is designed to target malignant B-cells via dual inhibition of PI3Kδ (promoting apoptosis and inhibiting survival) and BTK (blocking B-cell receptor signaling crucial for cell proliferation)[3][7]. It is primarily under evaluation for the treatment of **relapsed/refractory B-cell malignancies** including follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma[1][4][5][7].

Other names

ME-401 + zanubrutinibzandelisib + zanubrutinib